[by Ji, Yong Jun] Gilead Sciences’ ‘Livdelzi capsules’ (seladelpar lysine dihydrate), a new treatment for primary biliary ...

(Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic ...

AGA and AASLD offer six recommendations for the diagnosis and management of PBC: Use SP100 and GP210 antibodies to help diagnose suspected PBC in those who test negative for antimitochondrial ...

US gastroenterology and liver disease associations issued joint guidelines on diagnosing and treating primary biliary ...

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...

Gilead Sciences, Inc. announced that it will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver ...

For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...

Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of 24 ...

Dr David Johnson reviews findings from ACG 2026 on EoE, MASH, primary sclerosing cholangitis, and persistent reflux, plus ...

The Ministry of Food and Drug Safety (MFDS) said Tuesday it approved Livdelzi (seladelpar lysine dihydrate), an orphan drug ...

Agencies aligned on trial design, endpoints and safety database; FDA agreed NDA-enabling studies can run in parallel with ...

Life science investment firm KD Ventures' portfolio company Umecrine Cognition has received a preliminary patent allowance from the U.S. Patent and Trademark Office, USPTO, for the treatment of ...